Aclarion to Present at ROTH Conference, Showcasing Nociscan Technology and Financial Position

Aclarion, Inc., a commercial-stage healthcare technology company, announced it will participate in the 38th Annual ROTH Conference from March 22-24, 2026, in Dana Point, California. During the conference, CEO Brent Ness will engage in one-on-one meetings with institutional investors and analysts to discuss the company's progress advancing Nociscan, its proprietary MR spectroscopy platform designed to help physicians identify painful discs in patients suffering from chronic low back pain.

The company's participation in this prominent investment conference underscores the significance of its technology in addressing the chronic low back pain market. Nociscan represents the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology leverages Magnetic Resonance Spectroscopy, proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to provide critical insights into the location of a patient's low back pain.

CEO Brent Ness emphasized the company's strategic position, stating, "We look forward to engaging with the investment community at ROTH to share the progress we are making and the important catalysts ahead for Aclarion. With a strong balance sheet, no debt, and a focused strategy to expand adoption of Nociscan in both the UK and US, we believe we are well positioned to execute on the significant opportunity ahead." This financial stability provides Aclarion with a competitive advantage as it seeks to expand market adoption of its technology.

The company's forward-looking statements in the press release indicate ongoing clinical trial enrollment with an initial interim data readout expected to be internally available at the end of Q3. These developments are particularly important given the substantial market need for improved diagnostic tools in chronic low back pain management. For more information about the company, investors can visit www.aclarion.com.

Aclarion's technology operates through a cloud connection that receives magnetic resonance spectroscopy data from MRI machines for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. This biomarker data is then entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides physicians with clarity to optimize treatment strategies for patients suffering from chronic low back pain.

The company's participation in the ROTH Conference comes at a crucial time as it works to expand adoption of Nociscan in key markets. Investors and analysts attending the conference will have the opportunity to learn more about the company's regulatory and commercialization activities, as well as the potential benefits of the Nociscan technology. Additional company information and updates are available through various channels, including the latest news section at https://tinyurl.com/aconnewsroom.